A Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection in Adult Renal Transplant Recipients

Trial Profile

A Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection in Adult Renal Transplant Recipients

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2018

At a glance

  • Drugs Complement C1 inhibitor protein (Primary) ; Complement C1 inhibitor protein (Primary)
  • Indications Transplant rejection
  • Focus Therapeutic Use
  • Sponsors CSL Behring
  • Most Recent Events

    • 26 Jul 2018 Planned End Date changed from 16 Oct 2023 to 15 Jan 2026.
    • 26 Jul 2018 Planned primary completion date changed from 16 Jul 2020 to 15 Jan 2026.
    • 07 Sep 2017 Planned End Date changed from 1 Jul 2020 to 16 Oct 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top